HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head & …, 2014 - Wiley Online Library
Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …
被引用次数：41 相关文章

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head & Neck, 2014 - infona.pl
Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …
[HTML] nih.gov

[HTML][HTML] HRAS Mutations and Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Head and Neck Squamous Cell Carcinoma …

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head & neck, 2014 - ncbi.nlm.nih.gov
Background This was to identify mechanisms of innate resistance to an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck …

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head & Neck, 2014 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
The purpose of this study was to identify mechanisms of innate resistance to an epidermal …

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head & …, 2014 - search.ebscohost.com
Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head & …, 2014 - pubmed.ncbi.nlm.nih.gov
Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head and Neck, 2014 - pure.psu.edu
Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

JH Hah, M Zhao, CR Pickering… - Head and …, 2014 - mdanderson.elsevierpure.com
Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

JH Hah, M Zhao, CR Pickering, MJ Frederick… - Head & …, 2014 - europepmc.org
Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …
[PDF] researchgate.net

[PDF][PDF] HRAS Mutations and Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Head and Neck Squamous Cell Carcinoma …

MD Edward Kim, J Heymach - Head Neck, 2014 - researchgate.net
Background—This was to identify mechanisms of innate resistance to an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck …